Chronic Hepatitis C, Genotype 1
Conditions
Interventions
Trade Name: PegIntron
Product Name: Pegintron
Pharmaceutical Form: Injection*
Other descriptive name: PegIntron vials
Concentration unit: µg/ml microgram(s)/millilitre
Concentration number: 50-150
Ot
Sponsors
Integrated Therapeutics Group, Incorporated - a subsidiary of Schering-Plough
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - 18-70 years of age - Chronic Hepatitis C patients, non-responders to Pegasys/ribavirin treatment - no other interferon treatment except Pegasys - no other hepatitis C treatment - TSH within normal limits - Compensated liver disease with the following minimum hematologic and biochemical criteria at the Day 1 visit within normal limits: • Hemoglobin values of equal to or more than12 gm/dL for females and 13 gm/dL for males. • WBC equal to or more than 3,000/mm3 • Neutrophil count equal to or more than 1,500/mm3 • Platelet count equal to or more than 80,000/mm3 • Direct bilirubin within normal limits • Indirect bilirubin within normal limits (unless non-hepatitis related factors such as Gilbert's disease explain an indirect bilirubin rise). In such cases indirect bilirubin should be less than or equal to 3.0 mg/dL (less than or equal to 51.3 µmol/L) • Albumin within normal limits • Serum creatinine within normal limits • Subject must be a non-responder, defined as having received and not having responded to a prior treatment consisting of one course of Pegasys 180 mcg QW in combination with ribavirin 1000-1200 mg daily for a minimum of 12 weeks and: (a) Subject must be found to be HCV-RNA positive with less than a 2 log drop at 12 weeks of treatment or (b) is PCR positive at End Of Treatment whether End Of Treatment happened at week 48 or earlier Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - Pregnant females - subjects over 125kg - Previously untreated subjects - Subject discontinued from Pegasys due to adverse event - Subject is co-infected with HIV and/or HBV - Suspected hypersensitivity to interferon alpha or pegintron or ribavirin - Subject has had organ transplants - History of hepatocellular carcinoma, known coagulation disorders, G6PD deficiency, moderate to severe depression, craniocerebral trauma or active seizure disorders, cardiovascular dysfunction, chronic lung disease, immune-mediated disease, clinical gout, creatinine clearance less than 50 ml/min - Subject needs use of chronic systemic steroids - subject is active drug abuser.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To demonstrate that non-responders to Pegasys/ribavirin may respond to a weight-based Pegintron/Rebetol treatment.;Secondary Objective: Duration of response and safety.;Primary end point(s): Proportion of subjects who have achieved sustained virological response at 24 weeks post end of treatment | — |
Countries
Austria, Germany, Italy, Spain, United Kingdom
Outcome results
None listed